Navigation Links
Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
Date:4/24/2013

REDWOOD CITY, Calif., April 24, 2013 /PRNewswire/ --- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced top-line results demonstrating that a placebo-controlled, dose-finding, Phase 2 study of its investigational single-dose sublingual sufentanil NanoTab for acute pain, ARX-04, successfully met its primary endpoint.  Results demonstrated that patients receiving 30 mcg sufentanil NanoTab doses, administered by a healthcare professional, no more frequently than once per hour, had significantly greater pain reduction as measured by Summed Pain Intensity Difference to baseline during the 12-hour study period (SPID-12) than placebo-treated patients (p=0.003).  Adverse events reported in the study were generally mild-to-moderate in nature, with two serious adverse events of post-surgical infection reported, both of which were determined by the investigator to be unrelated to study drug.  Two patients dropped out of the study due to adverse events, one patient's discontinuation considered unrelated to study drug, and the other considered probably related to study drug, both in the 30 mcg-treated group.

"The goal of this program, to find an effective sublingual sufentanil dose that could be administered less frequently by a healthcare professional than our patient-administered ARX-01 product candidate, has been met", said Dr. Pamela Palmer , Chief Medical Officer, AcelRx Pharmaceuticals.  "There is a need for a non-invasive, rapid-onset strong analgesic to provide short-term treatment of pain for the wounded soldier on the battlefield, the trauma victim at the site of a road-traffic accident, the migraine patient in the emergency room, or in g
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
2. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
3. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
4. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
5. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
6. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
7. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
8. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
9. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
10. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Restore Health, a leading personalized medicine company ... it is now offering pharmacogenetics testing that provides ... upon their particular genetic makeup. Comprehensive medication management ... a patient,s genetics and their entire drug regimen.  ... this new service to healthcare providers and their ...
(Date:7/24/2014)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical ... proprietary products to treat voiding dysfunctions, today reported ... ended June 30, 2014.  Global revenue for ... 19% to $4.1 million, as compared to $3.4 ... year.  Total revenue for the fiscal first quarter ...
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... , REDWOOD CITY, Calif., Dec. 24 Maxygen, Inc. ... development of improved versions of protein drugs, today announced the ... expired at 5:00 p.m., New York City time, on December ... by the depositary for the tender offer, Maxygen expects to ...
... , , GREENSBORO, N.C., Dec. 23 ... four users who allege kidney damage due to the use ... in preparation for a colonoscopy. (Holshouser et al v. ... are against two Morrisville, N.C., pharmaceutical companies, Salix Pharmaceuticals, Ltd., ...
Cached Medicine Technology:Maxygen, Inc. Announces Preliminary Results of Dutch Auction Tender Offer 2Suits Commenced Against Maker of Prescription Cleansing Drug 2
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July 24, 2014 (HealthDay ... kids as unhealthy or recognize the health consequences of excess ... children of the families surveyed for the new research were ... Providence, R.I. "A third categorized their child,s health as ... now an assistant professor of pediatrics at the University of ...
(Date:7/24/2014)... University School of Medicine researchers may have found a ... They discovered that pre-treatment of neurons with the anti-aging ... of the toxic amyloid protein and glutamate. These findings ... . , Alzheimer,s disease is the most frequent ... of people age 65 and older and more than ...
(Date:7/24/2014)... 2014 News Facts , Lexmark’s ... achieved certification for compliance with Department of Defense ... the DoD Information Assurance Certification and Accreditation Process ... within the DoD as the Enterprise Clinical Imaging ... from the U.S. Army Medical Materiel Agency. , ...
(Date:7/24/2014)... choosing between two or more equally positive outcomes ... associated with activity in different regions of the ... an associate research scholar at the Princeton Neuroscience ... experiment, 42 people rated the desirability of more ... they looked at images of paired products with ...
(Date:7/24/2014)... NJ (PRWEB) July 24, 2014 Horizon ... will give one lucky family a rent-free week in ... until August 3, 2014. Don’t miss your chance to ... sweepstakes is open to all New Jersey residents, 25 ... BCBSNJ Facebook page, http://www.facebook.com/HorizonBCBSNJ . , “A ...
Breaking Medicine News(10 mins):Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2
... adults who are heavy users of marijuana are ... development, according to a new study. Pediatric researchers ... interconnect brain regions involved in memory, attention, decision-making, ... of particular concern because adolescence is a crucial ...
... 2 The Spastic Paraplegia Foundation (SPF) is ... (PLS) Awareness Month, part of a national effort ... that affects tens of thousands of families across ... )"It is important that we create greater awareness ...
... Totally-Endoscopic Coronary Artery Bypasses (Tecab) , ATLANTA Feb. 2 ... MD, the pioneer and world leader in performing beating ... staff at Saint Joseph,s Hospital in Atlanta. Dr. Srivastava ... Medical Center where he served as assistant professor ...
... Fellowship" to Focus on Auto Safety AdvocacyWASHINGTON, Feb. 2 ... for Highway and Auto Safety (Advocates) announced today the ... DC offices. The program aims to develop public ... organizations, abiding interest in highway and auto safety. ...
... Board of Directors of ORBIS International is pleased to ... of the New York-based non-profit organization."We are very fortunate ... important time in the organization,s history. ORBIS has reached ... scope--how we deliver our work and maximize operational efficiency. ...
... hold the key, study finds , , MONDAY, Feb 2 (HealthDay ... treat and prevent colitis-associated cancer (CAC), a new study suggests. ... cells in the immune system, plays a key role in ... mice done at the University of California, San Diego, School ...
Cached Medicine News:Health News:Heavy marijuana use may damage developing brain in teens, young adults 2Health News:Foundation Kicks off First-Ever PLS Awareness Month 2Health News:Saint Joseph's Adds Renowned Cardiothoracic Surgeon 2Health News:Saint Joseph's Adds Renowned Cardiothoracic Surgeon 3Health News:Allstate and Advocates for Highway and Auto Safety Unveil Public Policy Fellowship Program 2Health News:Allstate and Advocates for Highway and Auto Safety Unveil Public Policy Fellowship Program 3Health News:ORBIS International Appoints New President 2
... Designed To Hold & Support A Dropping Lens ... & Phacoemulsification To ,Continue. Can ... Of A Cyclodialysis Spatula To Reach Into ... Salvage Lens Fragments With One Instrument. ...
... Are Available In Two Models: One Is Direct ... Jaws Close. The Other Model Is Reverse ... Compressed The Jaws Open., ,The Forceps Are 22g, ... Through A 1.1mm Incision. These Forceps Allow The ...
... Designed To Dial An Exact Extension Of ... Maximum Visibility, With Titanium Handle & Spring. ... In Tissue, And Can Also Be Dialed ... Autoclaveable, Made In The USA, Handle Guaranteed ...
... The 0.1mm Pierce Tip Opening ... Flap, Without The Need For A Separate Cystotome. ... Grasping Positions Without Elevating The Incision.,The Distal Jaws ... Blades Help To Prevent Inadvertent Pick Up Of ...
Medicine Products: